← All trials
NCT02683213
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Sep 1, 2019
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Karolinska InstituteLead sponsor
- The Swedish Research CouncilCollaborator
- Swedish Heart Lung FoundationCollaborator
- Konung Gustaf V:s och Drottning Victorias FrimurarestiftelseCollaborator
- Karolinska InstituteReponsible party - principal investigator
- Karolinska InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.